A second COVID-19 vaccine under trial has proved to be 94.5 percent effective in preventing the virus.
Moderna is the second US pharmaceutical company to report effective vaccine results alongside company Pfizer.
Although safety data and regulatory review is required, the US believes two vaccines may be approved for emergency use by December this year. Both vaccines have been developed with new technology called messenger RNA, which has been a powerful tool in fighting the virus.